Reducing drug costs using behavioural scienceStrategies inspired by opt-in, opt-out approach of pensionsBy Michael Biskey04/07/2014|Canadian HR Reporter|Last Updated: 04/07/2014 The health plan cost increases besieging Canadian companies are driven by many factors, including the availability of specialty drugs for treating rare and complex diseases. But the primary driver of drug cost inflation is a lack of informed patient decisions — decisions employers have the power to influence. Each year, about $3.9 billion is lost to drug-mix waste associated with the use of higher-cost medications that generate no additional health benefit, according to the Express Scripts Canada 2012 Drug Trend Report. Another $1.2 billion is wasted annually through patient decisions about where, how and when they fill their prescriptions. To Read the Full Story, Subscribe or Sign In Remember Me Forgot Password If you are a current Subscriber, please click here to set-up or update your login information.